Analyst Price Targets — RCEL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 28, 2026 12:52 pm | — | Lake Street | $12.00 | $10.48 | TheFly | Avita Medical price target raised to $12 from $8 at Lake Street |
| August 19, 2026 9:48 am | Ryan Zimmerman | BTIG | $11.00 | $9.85 | StreetInsider | Avita Medical Ltd. (RCEL) PT Raised to $11 at BTIG |
| August 7, 2026 9:32 am | Ryan Zimmerman | BTIG | $7.00 | $4.75 | StreetInsider | BTIG Upgrades Avita Medical Ltd. (RCEL) to Buy |
| May 15, 2026 11:45 am | — | Lake Street | $6.00 | $4.36 | TheFly | Avita Medical upgraded to Buy from Hold at Lake Street |
| March 26, 2026 2:17 pm | — | Northland Securities | $10.00 | $3.86 | TheFly | Avita Medical stock pullback creates buying opportunity, says Northland |
| January 16, 2026 1:35 pm | — | Lake Street | $3.50 | $3.60 | TheFly | Avita Medical price target raised to $3.50 from $3 at Lake Street |
| October 17, 2025 11:38 am | Frank Takkinen | Lake Street | $4.00 | $5.38 | TheFly | Avita Medical downgraded to Hold from Buy at Lake Street |
| January 8, 2025 2:00 pm | Brooks O'Neil | Lake Street | $14.00 | $14.06 | TheFly | Avita Medical price target lowered to $14 from $20 at Lake Street |
| May 14, 2024 3:04 am | Matt O'Brien | Piper Sandler | $9.00 | $8.35 | StreetInsider | Piper Sandler Downgrades Avita Medical Ltd. (RCEL) to Neutral |
Latest News for RCEL
VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that its senior management will participate in the following investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference – Thursday, September 10, 2026 | Investor meetings with Cary…
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
AVITA Medical's reimbursement is now becoming more predictable. I believe this removes one of their main adoption barriers going forward. The RECELL GO international rollout and PermeaDerm's positive clinical economics also broaden RCEL's long-term potential. Management said they should reach their cash flow breakeven target by Q4 2026, which would further derisk the stock as a whole.
Avita Medical NASDAQ: RCEL presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness skin grafting, compared with cadaveric allograft.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RCEL.
U.S. House Trading
No House trades found for RCEL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.